Ali Khamesipour, PhD

 

Ali Khamesipour, PhD – IRAN                                              

Professor, Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences.
 
415 Taleghani Avenue,
P.O. Box 14155-6383,
Tehran 1416613675, Iran
Phone: (98-21) 8897 0657,
mobile # 98 912 145 9634
Faxphone: (98-21) 8897 0658/8895 3804
 
e-mail: Khamesipour_ali@yahoo.com
 
Working on leishmaniasis from 1993, main interest leishmaniasis, cutaneous leishmaniasis immune response, vaccine and drug development and clinical.
 
Education:
Post-doctoral fellowship 8/1992 – 8/1993
University of California, Irvine, College of Medicine, Department of Pathology, Irvine, California, USA
PhD, Department of Medical Microbiology and Immunology, School of Medicine,
Southern Illinois University, Springfield, Ill. (1992)
Advisor: Professor and Head Dept., Morris D. Cooper PhD
Major: Microbiology and Immunology
MSPH, Department of Pathobiology, School of Public Health, Tehran University (1979)
Major: Pathobiology, Advisor: Farrokh Modabber PhD
BS, School of Medicine, Isfahan University, Iran (1976)
Major: Medical Technology
 
Professional Experience:
Professor 2011 – present: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
Associated professor 2005 – 2011: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
Assistant professor 1993 – 2005: Center for Research and Training in Skin Diseases and Leprosy, Tehran University of Medical Sciences, Tehran, Iran
Visiting Professor 1995-1998: Department of Biological Sciences, University of North Texas, Denton, Texas, USA
Research Fellow, 5/1988 – 7/1992: Southern Illinois University, School of Medicine, Department of Medical, Microbiology and Immunology, Springfield, Illinois USA8
Teaching Assistant 8/1987 – 5/1988: Southern Illinois University, Department of Microbiology, Carbondale, Illinois USA
Medical Laboratory Supervisor 12/1976 – 3/1986: Baharlou Hospital, Tehran University of Medical Sciences, Tehran, Iran
Clinical Laboratory Supervisor, 11/1983 – 4/1985: Public Health Clinic, Tehran, Iran
Research Assistant, 10/1976 – 6/1980: Tehran University, School of Public Health, Pathobiology Department, Tehran, Iran
Blood Bank Technician, 6/1974 – 5/1976: Isfahan University Hospital, Isfahan, Iran
 
Membership in professional associations:
Editorial Board of Clinical Reviews and Opinions, 2009-present
National committee on leishmaniasis management, 2088-present
Editorial Board of Iranian Journal of Arthropod-Borne Diseases, 2007-present
The Vienna Vaccine Safety Initiative, Implementation Working Group, 2007-present
Member of Research Council of Iran Molecular Medicine Network, since Jan 2005-present8
The Brighton Collaboration/allergy working group 2002-present
Editorial board, Iranian Journal of Dermatology, 1998-present
Board of consultants, Medical Journal of the Islamic Republic of Iran, 1997-2000
American Society for Microbiology 1988 – 1998
 
Additional Professional Activities:
International research reference group on Leishmaniasis and Human African Trypanosomiasis, and Chagas Disease, TDR/WHO, 2008-present
WHO/TDR Member Product Development Team, Leishmaniasis Vaccine. 1998-2002
WHO/TDR Steering Committee on Leishmaniases (observer) 1997
National Committee on Leishmaniases 1994-1998
National Committee on Tuberculosis 1994-1995
 
Co-investigator: 
Frequency of hepatitis B virus DNA in anti-HBc+, HBsAg– blood donors in Rasht, north of Iran, WHO/EMRO.
Preparation of LPD nanoparticles containing rgp63 and rLmaC1N as vaccine against cutaneous leishmaniasis.
Comparison of combination of Imiquimod cream plus Glucantime vs Glucantime alone in the treatment of Anthroponotic Cutaneous Leishmaniasis (ACL).
Field efficacy vaccine trial with Alum precipitated Leishmania major Antigen against canine visceral leishmaniasis (VL) in Meshkin-Shahr district, northwest Iran.
The dynamic of amastigote growth within macrophages in human cutaneous leishmaniasis.
Field trial of ALM vaccine efficacy against ACL in 6-8 year old in Bam. TDR/WHO ID No. 970214.
Itraconazole in treatment of cutaneous leishmaniasis. A multicenteric double blind placebo controlled study.  JANSSEN-CILA, ID No. JRF/ITR-INT-82.
An open trial to evaluate pulse therapy with oral itraconazole in the treatment of disto-lateral onychomycosis. Janssen Pharmacetica, ID No. A3042
Efficacy of killed Leishmania major vaccine against natural cutaneous leishmaniasis in adults and children older than 5. TDR/WHO, ID No. 94008
Immunogenicity of killed Leishmania major vaccine in human volunteers in non-endemic area. TDR/WHO, ID No. 940181
Topical Application of Human Recombinant Epidermal Growth Factor in the Treatment of Burned Patients. Center for Genetic Engineering and Biotechnology, Havana, Cuba.
Role of mucosal IgA in C. trachomatis genital infection, ID No. PA-93-034 NIH, USA.
Collaborator of five more TDR/WHO supported projects.
 
oral presentation, publication, thesis director/advisor, principle investigator,  additional training, teaching experience in pdf


CONTENT

SERVICES

Other Resources

Our Dermatology Online

Home
Current Issue
All Issues
Instruction for authors
Submit Manuscripts
Ethics in Publishing
For Reviewers
Readers
About
Editors & Publishers 
Statistics
Copyright
Contact Us